https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-08-11 / Int Immunopharmacol 2023 Oct;123:110722
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-08-11 / Int Immunopharmacol 2023 Oct;123:1107222023-08-11 00:00:002023-08-11 00:00:00Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-31 / Cancers (Basel) 2023 Jul;15(15)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-31 / Cancers (Basel) 2023 Jul;15(15)2023-07-31 00:00:002023-07-31 00:00:00Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-22282023-07-28 00:00:002024-04-17 15:08:24Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-26 / Life (Basel) 2023 Jul;13(8)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-26 / Life (Basel) 2023 Jul;13(8)2023-07-26 00:00:002023-07-26 00:00:00The Viral Knock: Ameliorating Cancer Treatment with Oncolytic Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-15 / J Immunol 2023 Jul;211(2):219-228
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-15 / J Immunol 2023 Jul;211(2):219-2282023-07-15 00:00:002024-01-16 09:10:27Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-07 / Neurooncol Adv 2023;5(1):vdad081
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-07 / Neurooncol Adv 2023;5(1):vdad0812023-07-07 00:00:002023-07-07 00:00:00Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-01 / Life (Basel) 2023 Jul;13(7)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-01 / Life (Basel) 2023 Jul;13(7)2023-07-01 00:00:002023-07-01 00:00:00Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-06-30 / Hum Vaccin Immunother 2023 Aug;19(2):2220629
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-06-30 / Hum Vaccin Immunother 2023 Aug;19(2):22206292023-06-30 00:00:002023-06-30 00:00:00A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-06-23 / Biomedicines 2023 Jun;11(7)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-06-23 / Biomedicines 2023 Jun;11(7)2023-06-23 00:00:002024-04-17 15:04:06The Application of Evidence-Based Medicine in Individualized Medicine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-05-03 / Hum Vaccin Immunother 2023 May;:2198467
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-05-03 / Hum Vaccin Immunother 2023 May;:21984672023-05-03 00:00:002023-05-03 00:00:00Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
